Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
SAB Biotherapeutics, Inc. (SABS)
USD3.43
+0.03 (+0.88%)
US NASDAQ Healthcare Biotechnology
Address
777 W 41st St. 33140
Miami Beach, FL, US
Miami Beach, FL, US
CEO
Samuel J. Reich
Website
sab.bio
IPO
2021-02-09
CIK 1833214 ISIN US78397T2024
Also trades on
NASDAQ Global Market · SABS (USD)
NASDAQ Global Market · SABSW (USD)
Description
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
News Sentiment (7d)
Based on only 1 article — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
| Target company | Ticker | Date | Filing |
|---|---|---|---|
| Big Cypress Acquisition Corp. | BCYPU | 2021-08-17 | View |
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD3.43
+0.03 (+0.88%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
866.9K
Beta
0.55
Float Shares
7.92M
Free Float %
82.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.69% | -13.40% | -7.18% | -5.97% | +16.77% | -3.21% | +92.55% | -58.86% | -96.34% | -96.43% | -96.43% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (7 ratings, all time)
Buy
Price Targets & DCF
Current price
3.43
Low
7.00
+104.1%
Consensus
8.50
+147.8%
Median
8.50
+147.8%
High
10.00
+191.5%
DCF (Unlevered)
0.04
-98.8%
DCF (Levered)
0.07
-97.8%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 8 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 2 |
7.00
+104.1%
|
| All Time | 5 |
6.20
+80.8%
|
Quality scores
Altman Z-Score
0.75
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
A
Overall Score
4 / 5
High
DCF Score
2 / 5
Medium
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
3 / 5
Medium
P/E Score
3 / 5
Medium
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-100.0%
-
EPS growth Biotechnology: +29.7%+78.5% ★ Q1'26: +37.5% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%+22.2% ★ Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+562.3% Q1'26: +476.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.36× ★ Q1'26: -0.08× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 3 EPS Ana. |
Dec 2027 4 Rev. Ana. 2 EPS Ana. |
Dec 2028 7 Rev. Ana. 6 EPS Ana. |
Dec 2029 3 Rev. Ana. 4 EPS Ana. |
Dec 2030 6 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
60.88M
est: 67.89M (-10.3%)
|
23.90M
est: 27.64M (-13.5%)
|
2.24M
est: 2.60M (-14.0%)
|
1.32M
est: 1.32M (-0.1%)
|
—
est: 166.7K (-100.0%)
|
333.3K
333.3K – 333.3K
+100.0% YoY
|
83.3K
83.3K – 83.3K
-75.0% YoY
|
11.87M
11.87M – 11.87M
+14,145.1% YoY
|
88.55M
88.55M – 88.55M
+645.9% YoY
|
231.38M
231.38M – 231.38M
+161.3% YoY
|
| EBITDA |
-15.20M
est: -33.94M (+55.2%)
|
-15.12M
est: -13.82M (-9.5%)
|
-38.13M
est: -979.7K (-3,792.4%)
|
-28.99M
est: -498.1K (-5,720.8%)
|
16.60M
est: -62.7K (+26,551.5%)
|
-125.5K
-125.5K – -125.5K
-100.0% YoY
|
-31.4K
-31.4K – -31.4K
+75.0% YoY
|
-4.47M
-4.47M – -4.47M
-14,145.3% YoY
|
-33.33M
-33.33M – -33.33M
-645.9% YoY
|
-87.10M
-87.10M – -87.10M
-161.3% YoY
|
| EBIT |
-16.85M
est: -36.31M (+53.6%)
|
-18.41M
est: -14.78M (-24.6%)
|
-41.88M
est: -1.07M (-3,830.4%)
|
-33.79M
est: -541.8K (-6,136.6%)
|
13.51M
est: -68.2K (+19,905.0%)
|
-136.5K
-136.5K – -136.5K
-100.0% YoY
|
-34.1K
-34.1K – -34.1K
+75.0% YoY
|
-4.86M
-4.86M – -4.86M
-14,145.3% YoY
|
-36.25M
-36.25M – -36.25M
-645.9% YoY
|
-94.73M
-94.73M – -94.73M
-161.3% YoY
|
| Net Income |
-17.15M
est: -17.83M (+3.8%)
|
-18.74M
est: -31.95M (+41.3%)
|
-42.19M
est: -372.09M (+88.7%)
|
-34.11M
est: -226.96M (+85.0%)
|
13.27M
est: 4.26M (+211.5%)
|
-65.01M
-74.31M – -47.69M
-1,625.6% YoY
|
-31.25M
-31.25M – -31.25M
+51.9% YoY
|
-44.42M
-67.65M – -21.18M
-42.1% YoY
|
-29.69M
-29.69M – -29.69M
+33.2% YoY
|
-11.50M
-11.50M – -11.50M
+61.3% YoY
|
| SGA |
17.09M
est: 254.34M (-93.3%)
|
16.38M
est: 103.53M (-84.2%)
|
23.80M
est: 10.21M (+133.2%)
|
9.28M
est: 5.19M (+78.7%)
|
14.60M
est: 653.6K (+2,133.8%)
|
1.31M
1.31M – 1.31M
+100.0% YoY
|
326.8K
326.8K – 326.8K
-75.0% YoY
|
46.56M
46.56M – 46.56M
+14,145.1% YoY
|
347.28M
347.28M – 347.28M
+645.9% YoY
|
907.43M
907.43M – 907.43M
+161.3% YoY
|
| EPS |
-3.94
est: -1.93 (-104.7%)
|
-4.31
est: -3.45 (-24.9%)
|
-7.64
est: -6.07 (-25.9%)
|
-3.68
est: -3.68 (+0.0%)
|
0.22
est: -0.38 (+157.6%)
|
-0.99
-1.21 – -0.78
-160.5% YoY
|
-0.51
-0.51 – -0.51
+48.8% YoY
|
-0.56
-1.10 – -0.35
-10.5% YoY
|
-0.48
-0.48 – -0.48
+14.0% YoY
|
-0.19
-0.19 – -0.19
+61.3% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-11 | Rodman & Renshaw | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | A | 4/5 | 2/5 | 4/5 | 5/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-08 | A | 4/5 | 2/5 | 3/5 | 5/5 | 3/5 | 4/5 | 5/5 |
| 2026-05-07 | A | 4/5 | 2/5 | 3/5 | 5/5 | 3/5 | 4/5 | 5/5 |
| 2026-05-06 | A | 4/5 | 2/5 | 3/5 | 5/5 | 3/5 | 4/5 | 5/5 |
| 2026-05-05 | A | 4/5 | 2/5 | 3/5 | 5/5 | 3/5 | 4/5 | 5/5 |
| 2026-05-04 | A | 4/5 | 2/5 | 3/5 | 5/5 | 3/5 | 4/5 | 5/5 |
| 2026-05-01 | A | 4/5 | 2/5 | 3/5 | 5/5 | 3/5 | 4/5 | 5/5 |
| 2026-04-30 | A | 4/5 | 2/5 | 3/5 | 5/5 | 3/5 | 4/5 | 5/5 |
| 2026-04-29 | A- | 4/5 | 2/5 | 3/5 | 5/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-28 | A- | 4/5 | 2/5 | 3/5 | 5/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-27 | A- | 4/5 | 2/5 | 3/5 | 5/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-24 | A- | 4/5 | 2/5 | 3/5 | 5/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-23 | A- | 4/5 | 3/5 | 3/5 | 5/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-22 | A- | 4/5 | 3/5 | 3/5 | 5/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-21 | A- | 4/5 | 3/5 | 3/5 | 5/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-20 | A- | 4/5 | 3/5 | 3/5 | 5/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-17 | A- | 4/5 | 3/5 | 3/5 | 5/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-16 | A- | 4/5 | 3/5 | 3/5 | 5/5 | 2/5 | 3/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-47.22M
OE per share TTM
-2.20
Owner's Yield
-65.73%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
105.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
9
Total invested
3.64M
Insider transactions (90d)
0
Beneficial owners (>5%)
30
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Hamilton | 10.69M | 24.58% | 5.47M | 5.22M | 5.47M | 10.00 | IN | States | 2021-11-01 | ↗ |
| 2 | RTW Investments, LP | 9.22M | 9.99% | — | 9.22M | — | — | IA, PN | Delaware | 2024-02-14 | ↗ |
| 3 | Roderick Wong, M.D. | 9.22M | 9.99% | — | 9.22M | — | — | HC, IN | United States | 2024-02-14 | ↗ |
| 4 | BVF Inc. | 9.18M | 9.99% | — | — | — | 9.18M | CO | Delaware | 2023-12-04 | ↗ |
| 5 | BVF Partners L.P. | 9.18M | 9.99% | — | — | — | 9.18M | IA, PN | Delaware | 2023-12-04 | ↗ |
| 6 | Mark N. Lampert | 9.18M | 9.99% | — | — | — | 9.18M | IN | Delaware | 2023-12-04 | ↗ |
| 7 | BVF GP Holdings LLC | 8.62M | 9.40% | — | — | — | 8.62M | OO | Delaware | 2023-12-04 | ↗ |
| 8 | Capital LP | 6.93M | 9.90% | — | 6.93M | — | 6.93M | IA | Delaware, USA | 2023-10-16 | ↗ |
| 9 | Capital Master LP | 6.93M | 9.90% | — | 6.93M | — | 6.93M | OO | Delaware, USA | 2023-10-16 | ↗ |
| 10 | J. Sullivan, PhD | 5.71M | 13.12% | 5.71M | — | 5.71M | 10.00 | IN | States | 2021-11-01 | ↗ |
| 11 | BVF I GP LLC | 4.90M | 5.30% | — | — | — | 4.90M | OO | Delaware | 2023-12-04 | ↗ |
| 12 | Biotechnology Value Fund, L.P. | 4.90M | 5.30% | — | — | — | 4.90M | PN | Delaware | 2023-12-04 | ↗ |
| 13 | BVF II GP LLC | 3.72M | 4.10% | — | — | — | 3.72M | OO | Delaware | 2023-12-04 | ↗ |
| 14 | Biotechnology Value Fund II, L.P. | 3.72M | 4.10% | — | — | — | 3.72M | PN | Delaware | 2023-12-04 | ↗ |
| 15 | Katz | 3.05M | 7.00% | — | 3.05M | — | 10.00 | IN | States | 2021-11-02 | ↗ |
| 16 | J. Reich | 3.05M | 7.00% | — | 3.05M | — | 10.00 | IN | States | 2021-11-02 | ↗ |
| 17 | Cypress Holdings LLC | 3.05M | 7.00% | 3.05M | — | 3.05M | 10.00 | PN | Delaware | 2021-11-02 | ↗ |
| 18 | Christopher Hinkel | 1.30M | 8.77% | — | 1.30M | — | — | HC, IN | United States of America | 2021-10-19 | ↗ |
| 19 | RGC Management Company, LLC | 1.30M | 8.77% | — | 1.30M | — | — | HC, OO | Delaware | 2021-10-19 | ↗ |
| 20 | Radcliffe Capital Management, L.P. | 1.30M | 8.77% | — | 1.30M | — | — | IA, PN | Delaware | 2021-10-19 | ↗ |
| 21 | Radcliffe SPAC GP, LLC | 1.30M | 8.77% | — | 1.30M | — | — | HC, OO | Delaware | 2021-10-19 | ↗ |
| 22 | Radcliffe SPAC Master Fund, L.P. | 1.30M | 8.77% | — | 1.30M | — | — | PN, OO | Cayman Islands | 2021-10-19 | ↗ |
| 23 | Steven B. Katznelson | 1.30M | 8.77% | — | 1.30M | — | — | HC, IN | Canada, United States of America and the United Kingdom | 2021-10-19 | ↗ |
| 24 | BASSO CAPITAL MANAGEMENT, L.P. | 757.8K | 5.12% | — | 757.8K | — | 757.8K | IA, PN | Delaware | 2021-02-24 | ↗ |
| 25 | BASSO GP, LLC | 757.8K | 5.12% | — | 757.8K | — | 757.8K | HC, OO | Delaware | 2021-02-24 | ↗ |
| 26 | BASSO MANAGEMENT, LLC | 757.8K | 5.12% | — | 757.8K | — | 757.8K | OO | Delaware | 2021-02-24 | ↗ |
| 27 | BASSO SPAC FUND LLC | 757.8K | 5.12% | — | 757.8K | — | 757.8K | OO | Delaware | 2021-02-24 | ↗ |
| 28 | HOWARD I. FISCHER | 757.8K | 5.12% | — | 757.8K | — | 757.8K | HC, IN | Delaware | 2021-02-24 | ↗ |
| 29 | BVF Partners OS Ltd. | 434.9K | 1.00% | — | — | — | 434.9K | CO | Delaware | 2023-12-04 | ↗ |
| 30 | Biotechnology Value Trading Fund OS LP | 434.9K | 1.00% | — | — | — | 434.9K | PN | Delaware | 2023-12-04 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
9
-39 vs prev Q
New positions
3
Closed positions
42
Increased
5
Reduced
1
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 2.20M +2.2M (+100.0%) | 8.22B +8.2B (+100.0%) | 20.62% +20.623 pp | 2.72% +2.717 pp | USD3.74 +0.0% | 1 qtrs NEW |
| 2 | VIVO CAPITAL, LLC | 11.42M +— (+0.0%) | 42.71M +19.8M (+86.1%) | 107.12% +0.000 pp | 2.76% +0.914 pp | USD2.01 +86.1% | 2 qtrs — |
| 3 | RA CAPITAL MANAGEMENT, L.P. | 4.40M +— (+0.0%) | 16.46M +7.6M (+86.1%) | 41.29% +0.000 pp | 0.17% +0.060 pp | USD2.01 +86.1% | 2 qtrs — |
| 4 | COMMODORE CAPITAL LP | 4.40M +— (+0.0%) | 16.46M +7.6M (+86.1%) | 41.29% +0.000 pp | 1.10% +0.664 pp | USD2.01 +86.1% | 2 qtrs — |
| 5 | WOODLINE PARTNERS LP | 2.85M +— (+0.0%) | 10.66M +4.9M (+86.1%) | 26.74% +0.000 pp | 0.04% +0.014 pp | USD2.01 +86.1% | 2 qtrs — |
| 6 | SESSA CAPITAL IM, L.P. | 2.20M +— (+0.0%) | 8.22M +3.8M (+86.1%) | 20.62% +0.000 pp | 0.15% +0.049 pp | USD2.49 +50.2% | 8 qtrs — |
| 7 | BLACKSTONE INC. | 2.14M +2.1M (+100.0%) | 8.02M +8.0M (+100.0%) | 20.11% +20.108 pp | 0.03% +0.032 pp | USD3.74 +0.0% | 1 qtrs NEW |
| 8 | VANGUARD GROUP INC | 1.85M +1.5M (+405.0%) | 6.91M +6.2M (+839.7%) | 17.33% +13.896 pp | 0.00% +0.000 pp | USD3.67 +1.9% | 8 qtrs — |
| 9 | PERCEPTIVE ADVISORS LLC | 803.2K +803.2K (+100.0%) | 3.00M +3.0M (+100.0%) | 7.53% +7.534 pp | 0.05% +0.054 pp | USD3.74 +0.0% | 1 qtrs NEW |
| 10 | PROPEL BIO MANAGEMENT, LLC | 652.9K +652.9K (+100.0%) | 2.44M +2.4M (+100.0%) | 6.12% +6.124 pp | 2.08% +2.085 pp | USD3.74 +0.0% | 1 qtrs NEW |
| 11 | JEFFERIES FINANCIAL GROUP INC. | 580.3K +580.3K (+100.0%) | 2.17M +2.2M (+100.0%) | 5.44% +5.444 pp | 0.01% +0.011 pp | USD3.74 +0.0% | 1 qtrs NEW |
| 12 | BALYASNY ASSET MANAGEMENT L.P. | 475.4K +475.4K (+100.0%) | 1.78M +1.8M (+100.0%) | 4.46% +4.460 pp | 0.00% +0.002 pp | USD3.74 +0.0% | 1 qtrs NEW |
| 13 | MILLENNIUM MANAGEMENT LLC | 324.1K +324.1K (+100.0%) | 1.21M +1.2M (+100.0%) | 3.04% +3.040 pp | 0.00% +0.001 pp | USD3.74 +0.0% | 1 qtrs NEW |
| 14 | HB WEALTH MANAGEMENT, LLC | 307.5K +— (+0.0%) | 1.15M +532.0K (+86.1%) | 2.88% +0.000 pp | 0.01% +0.003 pp | USD2.01 +86.1% | 6 qtrs — |
| 15 | AMERIPRISE FINANCIAL INC | 283.6K +283.6K (+100.0%) | 1.06M +1.1M (+100.0%) | 2.66% +2.661 pp | 0.00% +0.000 pp | USD3.74 +0.0% | 1 qtrs NEW |
| 16 | MARSHALL WACE, LLP | 236.5K +236.5K (+100.0%) | 884.4K +884.4K (+100.0%) | 2.22% +2.218 pp | 0.00% +0.001 pp | USD3.74 +0.0% | 1 qtrs NEW |
| 17 | SIMPLIFY ASSET MANAGEMENT INC. | 208.2K +208.2K (+100.0%) | 778.8K +778.8K (+100.0%) | 1.95% +1.953 pp | 0.01% +0.013 pp | USD3.74 +0.0% | 1 qtrs NEW |
| 18 | AWM INVESTMENT COMPANY, INC. | 200.0K +— (+0.0%) | 748.0K +346.0K (+86.1%) | 1.88% +0.000 pp | 0.07% +0.035 pp | USD2.01 +86.1% | 2 qtrs — |
| 19 | STEMPOINT CAPITAL LP | 146.6K +146.6K (+100.0%) | 548.1K +548.1K (+100.0%) | 1.37% +1.375 pp | 0.09% +0.094 pp | USD3.74 +0.0% | 1 qtrs NEW |
| 20 | GEODE CAPITAL MANAGEMENT, LLC | 119.5K +33.8K (+39.4%) | 447.0K +274.7K (+159.4%) | 1.12% +0.317 pp | 0.00% +0.000 pp | USD3.84 -2.6% | 8 qtrs — |
| 21 | EXODUSPOINT CAPITAL MANAGEMENT, LP | 86.1K +86.1K (+100.0%) | 322.1K +322.1K (+100.0%) | 0.81% +0.808 pp | 0.00% +0.003 pp | USD3.74 +0.0% | 1 qtrs NEW |
| 22 | GOLDMAN SACHS GROUP INC | 51.3K +40.1K (+357.6%) | 192.0K +169.5K (+751.5%) | 0.48% +0.376 pp | 0.00% +0.000 pp | USD3.36 +11.3% | 2 qtrs — |
| 23 | PATHSTONE HOLDINGS, LLC | 50.7K +— (+0.0%) | 189.4K +87.6K (+86.1%) | 0.48% +0.000 pp | 0.00% +0.000 pp | USD4.29 -12.8% | 8 qtrs — |
| 24 | OMERS ADMINISTRATION CORP | 42.0K +42.0K (+100.0%) | 157.1K +157.1K (+100.0%) | 0.39% +0.394 pp | 0.00% +0.001 pp | USD3.74 +0.0% | 1 qtrs NEW |
| 25 | QUBE RESEARCH & TECHNOLOGIES LTD | 31.1K +31.1K (+100.0%) | 116.5K +116.5K (+100.0%) | 0.29% +0.292 pp | 0.00% +0.000 pp | USD3.74 +0.0% | 1 qtrs NEW |
| 26 | CITIGROUP INC | 30.0K +29.1K (+3,502.6%) | 112.1K +110.4K (+6,604.7%) | 0.28% +0.273 pp | 0.00% +0.000 pp | USD3.69 +1.4% | 2 qtrs — |
| 27 | VERITION FUND MANAGEMENT LLC | 26.9K +26.9K (+100.0%) | 100.5K +100.5K (+100.0%) | 0.25% +0.252 pp | 0.00% +0.000 pp | USD3.74 +0.0% | 1 qtrs NEW |
| 28 | ADAR1 CAPITAL MANAGEMENT, LLC | 26.3K +11.3K (+75.6%) | 98.5K +68.4K (+226.8%) | 0.25% +0.106 pp | 0.01% +0.004 pp | USD2.75 +36.0% | 2 qtrs — |
| 29 | PERSISTENT ASSET PARTNERS LTD | 19.8K +19.8K (+100.0%) | 74.0K +74.0K (+100.0%) | 0.19% +0.186 pp | 0.03% +0.033 pp | USD3.74 +0.0% | 1 qtrs NEW |
| 30 | COLONY GROUP, LLC | 19.2K +19.2K (+100.0%) | 71.8K +71.8K (+100.0%) | 0.18% +0.180 pp | 0.00% +0.000 pp | USD3.74 +0.0% | 1 qtrs NEW |
| 31 | FIRST PREMIER BANK | 19.0K +— (+0.0%) | 71.0K +33.0K (+86.8%) | 0.18% +0.000 pp | 0.02% +0.008 pp | USD3.04 +23.0% | 7 qtrs — |
| 32 | CITADEL ADVISORS LLC | 17.7K +17.7K (+100.0%) | 66.0K +66.0K (+100.0%) | 0.17% +0.166 pp | 0.00% +0.000 pp | USD3.74 +0.0% | 3 qtrs — |
| 33 | BLACKROCK, INC. | 17.2K +10.9K (+172.0%) | 64.5K +51.7K (+406.0%) | 0.16% +0.102 pp | 0.00% +0.000 pp | USD3.37 +11.0% | 6 qtrs — |
| 34 | NORTHERN TRUST CORP | 16.4K +5.0K (+44.1%) | 61.4K +38.5K (+168.2%) | 0.15% +0.047 pp | 0.00% +0.000 pp | USD3.77 -0.8% | 5 qtrs — |
| 35 | FIFTH LANE CAPITAL, LP | 15.0K +15.0K (+100.0%) | 56.1K +56.1K (+100.0%) | 0.14% +0.141 pp | 0.04% +0.043 pp | USD3.74 +0.0% | 1 qtrs NEW |
| 36 | STATE STREET CORP | 13.1K +13.1K (+100.0%) | 49.1K +49.1K (+100.0%) | 0.12% +0.123 pp | 0.00% +0.000 pp | USD3.74 +0.0% | 1 qtrs NEW |
| 37 | KESTRA ADVISORY SERVICES, LLC | 11.6K -380.0 (-3.2%) | 43.2K +19.2K (+80.1%) | 0.11% -0.004 pp | 0.00% +0.000 pp | USD2.70 +38.5% | 6 qtrs — |
| 38 | BANK OF AMERICA CORP /DE/ | 10.6K +10.5K (+14,241.9%) | 39.7K +39.5K (+26,539.6%) | 0.10% +0.099 pp | 0.00% +0.000 pp | USD3.73 +0.3% | 7 qtrs — |
| 39 | CAXTON CORP | 10.5K -408.0 (-3.7%) | 39.4K +17.4K (+79.1%) | 0.10% -0.004 pp | 0.92% +0.824 pp | USD2.01 +86.1% | 2 qtrs — |
| 40 | STATE OF WYOMING | 9.0K +9.0K (+100.0%) | 33.6K +33.6K (+100.0%) | 0.08% +0.084 pp | 0.00% +0.004 pp | USD3.74 +0.0% | 1 qtrs NEW |
| 41 | UBS GROUP AG | 7.4K -5.8K (-44.0%) | 27.7K +1.1K (+4.1%) | 0.07% -0.055 pp | 0.00% +0.000 pp | USD1.82 +105.5% | 5 qtrs — |
| 42 | ADVISOR GROUP HOLDINGS, INC. | 5.0K +200.0 (+4.1%) | 18.8K +8.8K (+88.0%) | 0.05% +0.002 pp | 0.00% +0.000 pp | USD4.22 -11.4% | 8 qtrs — |
| 43 | MORGAN STANLEY | 4.3K +4.1K (+2,436.9%) | 15.9K +15.6K (+4,616.0%) | 0.04% +0.038 pp | 0.00% +0.000 pp | USD3.76 -0.5% | 8 qtrs — |
| 44 | JPMORGAN CHASE & CO | 2.0K +1.9K (+2,187.4%) | 7.4K +7.3K (+4,152.6%) | 0.02% +0.018 pp | 0.00% +0.000 pp | USD3.76 -0.5% | 8 qtrs — |
| 45 | MAI CAPITAL MANAGEMENT | 217.00 +— (+0.0%) | 812.00 +375.0 (+85.8%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.81 +33.1% | 5 qtrs — |
| 46 | GS INVESTMENTS, INC. | 200.00 +— (+0.0%) | 748.00 +346.0 (+86.1%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD4.29 -12.8% | 8 qtrs — |
| 47 | HARBOUR INVESTMENTS, INC. | 50.00 +— (+0.0%) | 187.00 +86.0 (+85.1%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD4.28 -12.6% | 8 qtrs — |
| 48 | SBI SECURITIES CO., LTD. | 50.00 -2.0 (-3.8%) | 187.00 +82.0 (+78.1%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.38 +171.0% | 4 qtrs — |
| 49 | KOVITZ INVESTMENT GROUP PARTNERS, LLC | — -19.2K (-100.0%) | — -38.6K (-100.0%) | 0.00% -0.180 pp | 0.00% 0.000 pp | USD— | 6 qtrs SOLD |
| 50 | VIRTU FINANCIAL LLC | — -20.0K (-100.0%) | — -40.0K (-100.0%) | 0.00% -0.187 pp | 0.00% -0.002 pp | USD— | 2 qtrs SOLD |
| 51 | DIMENSIONAL FUND ADVISORS LP | — -15.8K (-100.0%) | — -31.7K (-100.0%) | 0.00% -0.148 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 52 | BVF INC/IL | — -932.7K (-100.0%) | — -1.9M (-100.0%) | 0.00% -8.749 pp | 0.00% -0.076 pp | USD— | 8 qtrs SOLD |
| 53 | SPHERA FUNDS MANAGEMENT LTD. | — -566.4K (-100.0%) | — -1.1M (-100.0%) | 0.00% -5.313 pp | 0.00% -0.240 pp | USD— | 2 qtrs SOLD |
| 54 | BARCLAYS PLC | — -10.0 (-100.0%) | — -27.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 55 | RENAISSANCE TECHNOLOGIES LLC | — -80.8K (-100.0%) | — -162.5K (-100.0%) | 0.00% -0.758 pp | 0.00% 0.000 pp | USD— | 4 qtrs SOLD |
| 56 | TOWER RESEARCH CAPITAL LLC (TRC) | — -1.6K (-100.0%) | — -3.1K (-100.0%) | 0.00% -0.015 pp | 0.00% 0.000 pp | USD— | 8 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 37 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Simplify Propel Opportunities ETF SURI | 0.52% | 400.5K | 2.82% |
| 2 | ALPS Medical Breakthroughs ETF SBIO | 0.15% | 319.0K | 0.50% |
| 3 | iShares Micro-Cap ETF IWC | 0.04% | 555.9K | 0.60% |
| 4 | Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF GSSC | 0.02% | 199.2K | 0.20% |
| 5 | Avantis U.S. Small Cap Equity ETF AVSC | 0.01% | 324.5K | 0.25% |
| 6 | iShares Russell 2000 Value ETF IWN | 0.01% | 1.45M | 0.24% |
| 7 | Xtrackers Russell 2000 UCITS ETF 1C XRSU.L | 0.01% | 153.8K | 0.30% |
| 8 | Global X - Russell 2000 ETF RSSL | 0.01% | 77.6K | 0.08% |
| 9 | Invesco Russell 2000 UCITS ETF RTYS.L | 0.01% | 16.7K | 0.25% |
| 10 | iShares Russell 2000 BuyWrite ETF IWMW | 0.00% | 2.8K | 0.39% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
7.00
Bullish
Ratio by volume
3.00
Bullish
Buys
7
Sells
1
Shares acquired
14.88M
Shares disposed
988.00
Cash buys
—
Cash sales
—
Net activity
+14,879,012
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-24 | Kropotova Alexandra | Officer | F-InKind | D | Common Stock | 988 | 0.00 | — | 43,296 | D | ↗ |
| 2026-02-03 | To Lucy | Officer | A-Award | A | Stock option (right to buy) | 2,400,000 | 4.45 | 10.68M | 2,400,000 | D | ↗ |
| 2026-02-03 | Sullivan Eddie Joe | Director / Officer | A-Award | A | Stock option (right to buy) | 3,000,000 | 4.45 | 13.35M | 3,000,000 | D | ↗ |
| 2026-02-03 | Reich Samuel J | Director / Officer | A-Award | A | Stock option (right to buy) | 4,800,000 | 4.45 | 21.36M | 4,800,000 | D | ↗ |
| 2026-02-03 | Kropotova Alexandra | Officer | A-Award | A | Stock option (right to buy) | 2,400,000 | 4.45 | 10.68M | 2,400,000 | D | ↗ |
| 2026-02-03 | Bausch Christoph Lawrence | Officer | A-Award | A | Stock option (right to buy) | 1,800,000 | 4.45 | 8.01M | 1,800,000 | D | ↗ |
| 2026-01-05 | ZACCARDELLI DAVID | Director | A-Award | A | Stock Option (right to buy) | 240,000 | 3.74 | 897.6K | 240,000 | D | ↗ |
| 2026-01-05 | Jain Rita | Director | A-Award | A | Stock Option (right to buy) | 240,000 | 3.74 | 897.6K | 240,000 | D | ↗ |
| 2025-12-16 | SKYLER JAY S | Director | A-Award | A | Stock Option (right to buy) | 150,000 | 3.99 | 598.5K | 150,000 | D | ↗ |
| 2025-12-16 | Polvino William James | Director | A-Award | A | Stock Option (right to buy) | 150,000 | 3.99 | 598.5K | 150,000 | D | ↗ |
| 2025-12-16 | Lucera Erick | Director | A-Award | A | Stock option (right to buy) | 150,000 | 3.99 | 598.5K | 150,000 | D | ↗ |
| 2025-12-16 | Link David | Director | A-Award | A | Stock Option (right to buy) | 150,000 | 3.99 | 598.5K | 150,000 | D | ↗ |
| 2025-12-16 | Giberson Scott | Director | A-Award | A | Stock Option (right to buy) | 150,000 | 3.99 | 598.5K | 150,000 | D | ↗ |
| 2025-12-16 | Ellias Helen K. | Director | A-Award | A | Stock Option (right to buy) | 150,000 | 3.99 | 598.5K | 150,000 | D | ↗ |
| 2025-12-11 | Kropotova Alexandra | Officer | F-InKind | D | Common Stock | 988 | 0.00 | — | 44,284 | D | ↗ |
| 2025-09-29 | Sessa Capital (Master), L.P. | Director | M-Exempt | A | Common Stock | 1,740,000 | 1.75 | 3.05M | 2,198,457 | D | ↗ |
| 2025-09-29 | Moin Andrew | Director | M-Exempt | D | Series B Convertible Preferred Stock | 17,400 | 1.75 | 30.5K | 211,100 | I | ↗ |
| 2025-09-19 | Kropotova Alexandra | Officer | F-InKind | D | Common Stock | 1,977 | 0.00 | — | 45,272 | D | ↗ |
| 2025-08-26 | To Lucy | Officer | A-Award | A | Stock Option (right to buy) | 1,200,000 | 2.17 | 2.60M | 1,200,000 | D | ↗ |
| 2025-08-26 | Sullivan Eddie Joe | Director / Officer | A-Award | A | Stock Option (right to buy) | 3,000,000 | 2.17 | 6.51M | 3,000,000 | D | ↗ |
| 2025-08-26 | Reich Samuel J | Director / Officer | A-Award | A | Stock Option (right to buy) | 4,800,000 | 2.17 | 10.42M | 4,800,000 | D | ↗ |
| 2025-08-26 | Kropotova Alexandra | Officer | A-Award | A | Stock Option (right to buy) | 2,400,000 | 2.17 | 5.21M | 2,400,000 | D | ↗ |
| 2025-08-26 | Bausch Christoph Lawrence | Officer | A-Award | A | Stock Option (right to buy) | 600,000 | 2.17 | 1.30M | 600,000 | D | ↗ |
| 2025-07-22 | Sessa Capital (Master), L.P. | Director | A-Award | A | Warrants (right to buy) | 114,250 | 218.75 | 24.99M | 114,250 | D | ↗ |
| 2025-07-22 | Moin Andrew | Director | A-Award | A | Series B Convertible Preferred Stock | 228,500 | 1.75 | 399.9K | 228,500 | I | ↗ |
| 2025-03-27 | Kropotova Alexandra | Officer | F-InKind | D | Common Stock | 1,179 | 0.00 | — | 47,249 | D | ↗ |
| 2024-12-18 | Kropotova Alexandra | Officer | F-InKind | D | Common Stock | 9,072 | 0.00 | — | 48,428 | D | ↗ |
| 2024-11-01 | Ellias Helen K. | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 3.88 | 77.6K | 20,000 | D | ↗ |
| 2024-08-12 | To Lucy | Officer | A-Award | A | Employee Stock Option (right to buy) | 125,000 | 2.35 | 293.8K | 125,000 | — | ↗ |
| 2024-07-26 | To Lucy | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-07-15 | Sullivan Eddie Joe | Director / Officer | A-Award | A | Stock Option (right to buy) | 46,528 | 5.40 | 251.3K | 46,528 | — | ↗ |
| 2024-07-15 | Spragens Jeffrey G | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 2.90 | 58.0K | 20,000 | — | ↗ |
| 2024-07-15 | SKYLER JAY S | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 2.90 | 58.0K | 20,000 | — | ↗ |
| 2024-07-15 | Reich Samuel J | Director / Officer | A-Award | A | Stock Option (right to buy) | 35,700 | 2.90 | 103.5K | 35,700 | — | ↗ |
| 2024-07-15 | Polvino William James | Director | A-Award | A | Stock Option (right to buy) | 13,958 | 2.90 | 40.5K | 13,958 | — | ↗ |
| 2024-07-15 | Lucera Erick | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 2.90 | 58.0K | 20,000 | — | ↗ |
| 2024-07-15 | Link David Charles | Director | A-Award | A | Stock Option (right to buy) | 9,305 | 2.90 | 27.0K | 9,305 | — | ↗ |
| 2024-07-15 | HAMILTON CHRISTINE E | Director | A-Award | A | Stock Option (right to buy) | 2,326 | 2.90 | 6.7K | 2,326 | — | ↗ |
| 2024-07-15 | Giberson Scott | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 2.90 | 58.0K | 20,000 | — | ↗ |
| 2024-06-04 | Conley Mark William | Officer | — | D | Employee Stock Option (right to buy) | 25,000 | 4.79 | 119.8K | 0 | — | ↗ |
| 2024-05-03 | SKYLER JAY S | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-02-21 | Sullivan Eddie Joe | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 190,000 | 5.17 | 982.3K | 190,000 | — | ↗ |
| 2024-02-21 | Reich Samuel J | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 434,000 | 5.17 | 2.24M | 434,000 | — | ↗ |
| 2024-02-21 | Kropotova Alexandra | Officer | A-Award | A | Employee Stock Option (right to buy) | 140,000 | 5.17 | 723.8K | 140,000 | — | ↗ |
| 2024-02-21 | King Michael | Officer | A-Award | A | Employee Stock Option (right to buy) | 115,000 | 5.17 | 594.6K | 115,000 | — | ↗ |
| 2024-02-21 | Bausch Christoph Lawrence | Officer | A-Award | A | Employee Stock Option (right to buy) | 140,000 | 5.17 | 723.8K | 140,000 | — | ↗ |
| 2023-12-07 | Sullivan Eddie Joe | Director / Officer | P-Purchase | A | Common Stock | 1,740 | 0.88 | 1.5K | 5,232,304 | — | ↗ |
| 2023-11-30 | King Michael | Officer | P-Purchase | A | Common Stock | 5,000 | 0.90 | 4.5K | 5,000 | — | ↗ |
| 2023-11-29 | Reich Samuel J | Director / Officer | P-Purchase | A | Common Stock | 11,000 | 0.89 | 9.8K | 219,001 | — | ↗ |
| 2023-11-24 | Sessa Capital (Master), L.P. | Director | M-Exempt | A | Common Stock | 4,584,571 | 0.00 | 458.46 | 4,584,571 | — | ↗ |
| 2023-11-24 | Moin Andrew | Director | M-Exempt | A | Series A-2 Convertible Preferred Stock | 28,380 | 0.63 | 17.9K | 28,380 | — | ↗ |
| 2023-11-24 | Ellias Helen K. | Director | M-Exempt | A | Common Stock | 2,857,142 | 0.00 | 285.71 | 2,857,142 | — | ↗ |
| 2023-11-14 | Ellias Helen K. | Director | — | I | Preferred Tranche B Warrants | 1,200 | 1,000.00 | 1.20M | 0 | — | ↗ |
| 2023-11-13 | Sessa Capital (Master), L.P. | Director | M-Exempt | D | Tranche A Warrants | 13,269 | 1,000.00 | 13.27M | 0 | — | ↗ |
| 2023-11-13 | Moin Andrew | Director | A-Award | A | Series A-1 Convertible Preferred Stock | 13,269 | 0.63 | 8.4K | 31,269 | — | ↗ |
| 2023-11-10 | Sessa Capital (Master), L.P. | Director | A-Award | A | Tranche C Warrants | 22,115 | 1,000.00 | 22.12M | 52,115 | — | ↗ |
| 2023-11-10 | Moin Andrew | Director | A-Award | A | Preferred Tranche A Warrants | 13,269 | 1,000.00 | 13.27M | 13,269 | — | ↗ |
| 2023-10-30 | King Michael | Officer | A-Award | A | Employee Stock Option (right to buy) | 850,000 | 0.80 | 678.3K | 850,000 | — | ↗ |
| 2023-10-23 | Sessa Capital (Master), L.P. | Director | M-Exempt | D | Tranche A Warrants | 16,269 | 1,000.00 | 16.27M | 0 | — | ↗ |
| 2023-10-23 | Moin Andrew | Director | A-Award | A | Series A-1 Convertible Preferred Stock | 16,269 | 0.63 | 10.2K | 18,000 | — | ↗ |
| 2023-10-02 | Sessa Capital (Master), L.P. | Director | — | D | Series A-1 Convertible Preferred Stock | 2,747,097 | 0.63 | 1.73M | 0 | — | ↗ |
| 2023-10-02 | Moin Andrew | Director | — | I | Series A-1 Convertible Preferred Stock | 2,747,097 | 0.63 | 1.73M | 0 | — | ↗ |
| 2023-04-03 | Lucera Erick | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-03-14 | Sullivan Eddie Joe | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 525,000 | 0.54 | 283.5K | 525,000 | — | ↗ |
| 2023-03-14 | Reich Samuel J | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 525,000 | 0.54 | 283.5K | 525,000 | — | ↗ |
| 2023-03-14 | Kropotova Alexandra | Officer | A-Award | A | Common Stock | 275,000 | 0.00 | — | 275,000 | — | ↗ |
| 2023-03-14 | Beyer Russell P | Officer | A-Award | A | Employee Stock Option (right to buy) | 275,000 | 0.54 | 148.5K | 275,000 | — | ↗ |
| 2023-03-14 | Bausch Christoph Lawrence | Officer | A-Award | A | Employee Stock Option (right to buy) | 275,000 | 0.54 | 148.5K | 275,000 | — | ↗ |
| 2023-02-28 | Spragens Jeffrey G | Director | J-Other | A | Warrants | 19,936 | 11.50 | 229.3K | 19,936 | — | ↗ |
| 2023-02-28 | Reich Samuel J | Director / Officer | J-Other | A | Warrants | 9,968 | 11.50 | 114.6K | 9,968 | — | ↗ |
| 2022-12-31 | HAMILTON CHRISTINE E | Director / 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 4,993,090 | — | ↗ |
| 2022-12-07 | Spragens Jeffrey G | Director | A-Award | A | Common Stock | 82,987 | 1.21 | 100.0K | 394,989 | — | ↗ |
| 2022-12-07 | Link David Charles | Director | A-Award | A | Common Stock | 41,493 | 1.21 | 50.0K | 57,313 | — | ↗ |
| 2022-12-07 | HAMILTON CHRISTINE E | Director | A-Award | A | Warrant (Common Stock) | 82,987 | 0.00 | — | 82,987 | — | ↗ |
| 2022-09-13 | Sullivan Eddie Joe | Director / Officer / 10% Owner | A-Award | A | Employee Stock Option (right to buy) | 35,000 | 0.71 | 24.9K | 35,000 | — | ↗ |
| 2022-09-13 | Reich Samuel J | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 525,000 | 0.71 | 372.8K | 525,000 | — | ↗ |
| 2022-09-13 | Kropotova Alexandra | Officer | A-Award | A | Employee Stock Option (right to buy) | 18,325 | 0.71 | 13.0K | 18,325 | — | ↗ |
| 2022-09-13 | HAMILTON CHRISTINE E | Director / 10% Owner | P-Purchase | A | Common Stock | 10,000 | 0.73 | 7.3K | 4,993,090 | — | ↗ |
| 2022-09-13 | Giberson Scott | Director | A-Award | A | Employee Stock Option (right to buy) | 25,000 | 0.71 | 17.8K | 25,000 | — | ↗ |
| 2022-09-13 | Beyer Russell P | Officer | A-Award | A | Employee Stock Option (right to buy) | 274,875 | 0.71 | 195.2K | 274,875 | — | ↗ |
| 2022-09-13 | Bausch Christoph Lawrence | Officer | A-Award | A | Employee Stock Option (right to buy) | 274,875 | 0.71 | 195.2K | 274,875 | — | ↗ |
| 2022-09-07 | Sullivan Eddie Joe | Officer | P-Purchase | A | Common Stock | 14,000 | 0.74 | 10.3K | 5,230,564 | — | ↗ |
| 2022-07-06 | Giberson Scott | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-06-06 | Kropotova Alexandra | Officer | A-Award | A | Common Stock | 300,000 | 0.00 | — | 300,000 | — | ↗ |
| 2022-05-20 | Spragens Jeffrey G | Director | J-Other | A | Common Stock | 299,002 | 0.00 | — | 312,002 | — | ↗ |
| 2022-05-20 | Reich Samuel J | Officer | J-Other | A | Common Stock | 207,001 | 0.00 | — | 208,001 | — | ↗ |
| 2022-03-16 | Ullerich Melissa Vera | Officer | A-Award | A | Employee Stock Option (right to buy) | 16,405 | 0.00 | — | 16,405 | — | ↗ |
| 2022-03-16 | Sullivan Eddie Joe | Officer | A-Award | A | Employee Stock Option (right to buy) | 21,218 | 0.00 | — | 21,218 | — | ↗ |
| 2022-03-16 | Reich Samuel J | Officer | A-Award | A | Employee Stock Option (right to buy) | 7,000 | 0.00 | — | 7,000 | — | ↗ |
| 2022-03-16 | Pommer Jerry Lynn | Officer | A-Award | A | Employee Stock Option (right to buy) | 15,172 | 0.00 | — | 15,172 | — | ↗ |
| 2022-03-16 | Luke Thomas Charles | Officer | A-Award | A | Employee Stock Option (right to buy) | 20,519 | 0.00 | — | 20,519 | — | ↗ |
| 2022-03-16 | Finnegan Frederick | Officer | A-Award | A | Employee Stock Option (right to buy) | 23,453 | 0.00 | — | 23,453 | — | ↗ |
| 2022-03-16 | Erickson Bruce Kipp | Officer | A-Award | A | Employee Stock Option (right to buy) | 18,196 | 0.00 | — | 18,196 | — | ↗ |
| 2022-03-16 | Beyer Russell P | Officer | A-Award | A | Employee Stock Option (right to buy) | 6,000 | 0.00 | — | 6,000 | — | ↗ |
| 2022-03-16 | Bausch Christoph Lawrence | Officer | A-Award | A | Employee Stock Option (right to buy) | 24,972 | 0.00 | — | 24,972 | — | ↗ |
| 2021-11-17 | Reich Samuel J | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 350,000 | 11.17 | 3.91M | 350,000 | — | ↗ |
| 2021-11-17 | Beyer Russell P | Officer | A-Award | A | Employee Stock Option (right to buy) | 110,000 | 11.17 | 1.23M | 110,000 | — | ↗ |
| 2021-10-26 | Beyer Russell P | Officer | S-Sale | D | Common Stock | 278 | 7.90 | 2.2K | 0 | — | ↗ |
| 2021-10-25 | Beyer Russell P | Officer | A-Award | A | Common Stock | 129 | 7.78 | 1.0K | 278 | — | ↗ |
| 2021-10-22 | Wu Hua | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-10-22 | Ullerich Melissa Vera | Officer | A-Award | A | Employee Stock Option (right to buy) | 6,979 | 1.25 | 8.7K | 6,979 | — | ↗ |
| 2021-10-22 | Turner Mervyn | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-10-22 | Sullivan Eddie Joe | Director / Officer / 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 2,800 | — | ↗ |
| 2021-10-22 | Randall Charles Hiram | Officer | A-Award | A | Employee Stock Option (right to buy) | 116,321 | 0.25 | 29.1K | 116,321 | — | ↗ |
| 2021-10-22 | Pommer Jerry Lynn | Officer | A-Award | A | Employee Stock Option (right to buy) | 69,793 | 0.25 | 17.4K | 69,793 | — | ↗ |
| 2021-10-22 | Polvino William James | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-10-22 | Luke Thomas Charles | Officer | — | D | Common Stock | 0 | 0.00 | — | 990 | — | ↗ |
| 2021-10-22 | Link David Charles | Director | A-Award | A | Employee Stock Option (right to buy) | 23,264 | 1.00 | 23.3K | 23,264 | — | ↗ |
| 2021-10-22 | Hamilton Edward D. | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 28,587 | — | ↗ |
| 2021-10-22 | HAMILTON CHRISTINE E | Director / 10% Owner | A-Award | A | Employee Stock Option (right to buy) | 23,264 | 1.25 | 29.1K | 23,264 | — | ↗ |
| 2021-10-22 | Finnegan Frederick | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-10-22 | Erickson Bruce Kipp | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-10-22 | Carillo Carlos N | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-10-22 | Beyer Russell P | Officer | — | D | Common Stock | 0 | 0.00 | — | 2,475 | — | ↗ |
| 2021-10-22 | Bausch Christoph Lawrence | Officer | A-Award | A | Employee Stock Option (right to buy) | 11,632 | 1.25 | 14.5K | 11,632 | D | ↗ |
| 2021-10-19 | Luke Thomas Charles | Officer | A-Award | A | Common Stock | 990 | 10.10 | 10.0K | 990 | — | ↗ |
| 2021-10-18 | Beyer Russell P | Officer | A-Award | A | Common Stock | 2,475 | 10.10 | 25.0K | 2,475 | — | ↗ |
| 2021-10-14 | Reich Samuel J | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 1,000 | 10.11 | 10.1K | 1,000 | — | ↗ |
| 2021-10-14 | Hamilton Edward D. | 10% Owner | A-Award | A | Common Stock | 5,092 | 10.10 | 51.4K | 5,092 | — | ↗ |
| 2021-10-14 | HAMILTON CHRISTINE E | Director / 10% Owner | A-Award | A | Common Stock | 5,092 | 10.10 | 51.4K | 5,092 | — | ↗ |
| 2021-10-13 | Katz Ilan | Director / 10% Owner | P-Purchase | A | Common Stock | 500 | 10.11 | 5.1K | 1,500 | — | ↗ |
| 2021-10-13 | Hamilton Edward D. | 10% Owner | A-Award | A | Common Stock | 20,800 | 10.10 | 210.1K | 20,800 | — | ↗ |
| 2021-10-13 | HAMILTON CHRISTINE E | Director / 10% Owner | A-Award | A | Common Stock | 20,800 | 10.10 | 210.1K | 20,800 | — | ↗ |
| 2021-10-12 | Hamilton Edward D. | 10% Owner | A-Award | A | Common Stock | 25,000 | 10.09 | 252.3K | 25,000 | — | ↗ |
| 2021-10-12 | HAMILTON CHRISTINE E | Director / 10% Owner | A-Award | A | Common Stock | 25,000 | 10.08 | 252.0K | 25,000 | — | ↗ |
| 2021-10-07 | Sullivan Eddie Joe | Director / Officer / 10% Owner | A-Award | A | Common Stock | 2,800 | 10.07 | 28.2K | 2,800 | — | ↗ |
| 2021-10-01 | Spragens Jeffrey G | Director | P-Purchase | A | Common Stock | 13,000 | 10.07 | 130.9K | 13,000 | — | ↗ |
| 2021-10-01 | Katz Ilan | Director / 10% Owner | P-Purchase | A | Common Stock | 1,000 | 10.09 | 10.1K | 1,000 | — | ↗ |
| 2021-10-01 | Hamilton Edward D. | 10% Owner | A-Award | A | Common Stock | 2,695 | 10.10 | 27.2K | 2,695 | — | ↗ |
| 2021-10-01 | HAMILTON CHRISTINE E | Director / 10% Owner | A-Award | A | Common Stock | 2,695 | 10.10 | 27.2K | 2,695 | — | ↗ |
| 2021-09-29 | Beyer Russell P | Officer | A-Award | A | Common Stock | 10 | 10.08 | 100.80 | 15 | — | ↗ |
| 2021-09-28 | Beyer Russell P | Officer | A-Award | A | Common Stock | 149 | 10.08 | 1.5K | 149 | — | ↗ |
| 2021-01-14 | Reich Samuel J | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 417,200 | 10.00 | 4.17M | 3,047,825 | — | ↗ |
| 2021-01-14 | Katz Ilan | Director / 10% Owner | P-Purchase | A | Common Stock | 417,200 | 10.00 | 4.17M | 3,047,825 | — | ↗ |
| 2021-01-14 | Big Cypress Holdings LLC | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 417,200 | 10.00 | 4.17M | 3,047,825 | — | ↗ |
| 2021-01-11 | Spragens Jeffrey G | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-01-11 | Reich Samuel J | Director / Officer / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 2,630,625 | — | ↗ |
| 2021-01-11 | Martin James Joseph | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-01-11 | Katz Ilan | Director / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 2,630,625 | — | ↗ |
| 2021-01-11 | Collins Stephen D. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-01-11 | Big Cypress Holdings LLC | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 2,630,625 | — | ↗ |
Executive team
Top executives
Shares Outstanding
9.56M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Samuel J. Reich | CEO & Director | 846.5K | male |
| Alexandra Kropotova | Executive Vice President & Chief Medical Officer | 832.2K | — |
| Eddie Joe Sullivan | Co-Founder, President & Director | 746.5K | — |
| Lucy To | Executive Vice President & Chief Financial Officer | 684.0K | female |
| Christoph Bausch | Executive Vice President & Chief Operating Officer | 609.0K | — |
| Hua Wu | Senior Vice President of Product Development | — | female |
| Carlos N. Carillo | Senior Vice President of Regulatory Affairs | — | — |
| Angie Parizek | Senior Vice President of Clinical Operations | — | female |
| Catherine DeRose | Vice President of Human Resources | — | female |
| Cristi Barnett | Vice President of Investor Relations & Corporate Communications | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SABS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
